A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma

Zhang, Haiyu; Hu, Bingshuang; Zhou, Jiaxiong; Li, Wen; Li, Minying

doi:10.1016/j.heliyon.2023.e16874

Heliyon

2023

DOI: 10.1016/j.heliyon.2023.e16874

|View full text |Cite

A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma

Haiyu Zhang¹,

Bingshuang Hu

Jiaxiong Zhou

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 29 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review

Zhou,

Qin,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundImmune checkpoint inhibitors (ICIs) have become a prevalent tool in anti-tumor therapy in recent years. They may cause immune-related adverse events (irAEs) including potentially life-threatening cardiovascular toxicities such as myocarditis.Case presentationIn this report, we describe a 69-year-old man with recurrent esophageal cancer who developed myocarditis after receiving three cycles of sintilimab combined with nab-paclitaxel. Despite a rising cardiac troponin I (cTnI), he initially reported no discomfort. He was later suspected of having with sintilimab-induced myocarditis. Although treatment with methylprednisolone reduced his cTnI levels, he still experienced significant discomfort. Moreover, he developed pneumonia and septic shock.ConclusionIn our literature search to identify all reported cases of sintilimab-associated adverse events involving myocarditis, we found 14 patients, including those with esophageal cancer, thymoma, lung cancer, gastric cancer, hepatobiliary carcinoma, and chordoma. The primary treatment for ICI-induced cardiotoxicity is methylprednisolone. However, the long-term or high-dose use of steroids can also induce side effects, which have not been the focus of these case reports. This is the first reported case of asymptomatic immune-mediated myocarditis occurring during the treatment of esophageal cancer with sintilimab. It is also the first to address the side effects of methylprednisolone used in the treatment of sintilimab-related myocarditis. To facilitate an early diagnosis, regular monitoring is required during sintilimab treatment. We should also focus on the prevention and management of adverse effects related to steroid use.

show abstract

Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review

Zhou,

Qin,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A case of acute myocarditis induced by PD-1 inhibitor (sintilimab) in the treatment of large cell neuroendocrine carcinoma

Cited by 1 publication

References 29 publications

Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review

Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review

Contact Info

Product

Resources

About